Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Lamivudine (Dovato -- ViiV healthcare ULC) indication: as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg

The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/lamivudine (DTG/3TC) be reimbursed as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 40 kg, only if the following conditions are met. The pa...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH October 2019, 2019
Edition:Version: 1.0
Series:CADTH common drug review
Subjects:
Canada
Hiv Integrase Inhibitors / Therapeutic Use
Hiv-1 / Drug Effects
Cost-benefit Analysis
Drug Therapy, Combination
Hiv Infections / Drug Therapy
Treatment Outcome
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/lamivudine (DTG/3TC) be reimbursed as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 40 kg, only if the following conditions are met. The patient must be naive to any antiretroviral therapy (ART) and have an HIV-1 viral load ≤ 500,000 copies/mL. The patient must be under the care of a practitioner experienced in the care of patients with HIV. The cost of DTG/3TC should not exceed the total drug plan cost of treatment with the least costly alternative regimen used for the treatment of HIV-1, including the individual components used in combination
Item Description:"Final."
Physical Description:1 PDF file (9 pages)

Similar Items